1.	Phase II Randomized Study of a Lymphodepleting Conditioning Regimen Comprising Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation Followed by Anti-MART-1 and Anti-gp100 T-Cell Receptor Gene-Engineered Autologous Peripheral Blood Lymphocytes, High-Dose Aldesleukin, and gp100:154-162 or MART-1:26-35(27L) Peptide Vaccination in Patients With Metastatic Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-09-C-0051, 09-C-0051, NCI-P08428, NCT00814684
2.	Phase I Pilot Study of Peptide Vaccine Comprising gp100:209-217(210M), MART-1:26-35(27L), gp100:280-288(288V), and NY-ESO-1 Emulsified in Montanide ISA 51 VG and Anti-PD-1 Human Monoclonal Antibody MDX-1106 in Patients With Unresectable Stage III or IV Melanoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 16 and over Sponsor: NCI Protocol IDs: MCC-15400, MCC-15400, 7997, NCT01176461
3.	Phase I Study of Anti-PD-1 Human Monoclonal Antibody MDX-1106 and Vaccine Therapy Comprising gp100:209-217(210M) Peptide, MART-1:26-35(27L) Peptide, gp100:280-288(288V) Peptide, NY-ESO-1 Peptide, and Montanide ISA 51 VG in Patients With Resected Stage IIIC or IV Melanoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 16 and over Sponsor: NCI Protocol IDs: MCC-15651, MCC-15651, 8316, NCT01176474